⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for A Non-interventional Study of REVLIMID® (Lenalidomide) Treatment of IPSS Low- or Intermediate-1-risk Myelodysplastic Syndromes Associated With a Deletion 5q or Refractory/Relapsed Mantle Cell Lymphoma in Korea

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: A Non-interventional Study of REVLIMID® (Lenalidomide) Treatment of IPSS Low- or Intermediate-1-risk Myelodysplastic Syndromes Associated With a Deletion 5q or Refractory/Relapsed Mantle Cell Lymphoma in Korea

Official Title: Post Marketing Surveillance on Safety Evaluation of REVLIMID® (Lenalidomide) Treatment of Myelodysplastic Syndromes Associated With a Deletion 5q or Mantle Cell Lymphoma in Korea

Study ID: NCT04036448

Interventions

REVLIMID®

Study Description

Brief Summary: The Drug Use Examination (DUE) is planned and designed for the safety evaluation of new indications after the approval of a new drug in Korea. This DUE is a non-interventional, observational and post-marketing surveillance, which will be conducted by collecting the safety information of REVLIMID® for new indications in routine clinical practice in Korea. Six-Hundred (600) adult patients, who start with REVLIMID® treatment based on the approved local package insert (PI) of REVLIMID® during routine clinical practice in Korea and have indications noted below. 1. Patients with transfusion-dependent anemia due to IPSS low- or intermediate-1-risk Myelodysplastic Syndromes associated with a deletion 5q cytogenetic abnormality (del \[5q\] MDS) 2. Patients with mantle cell lymphoma who have received at least one prior therapy (rrMCL) 3. Previously treated follicular lymphoma (FL), in combination with rituximab (an anti-CD20 antibody)

Detailed Description:

Eligibility

Minimum Age: 19 Years

Eligible Ages: ADULT, OLDER_ADULT

Sex: ALL

Healthy Volunteers: No

Locations

Local Institution - S02, Seoul-si, Seoul Teugbyeolsi, Korea, Republic of

Hallym University Medical Center, Anyang, , Korea, Republic of

Keimyung University Dongsan Hospital, Daegu, , Korea, Republic of

Kyungpook National University Hospital, Daegu, , Korea, Republic of

Local Institution - S03, Daegu, , Korea, Republic of

Local Institution - S07, Daegu, , Korea, Republic of

Local Institution - S11, Goyang, , Korea, Republic of

Local Institution - S04, Hwasun-gun, , Korea, Republic of

CHONNAM National University Hwasun Hospital, Hwasun, , Korea, Republic of

Naitonal Health Insurance Service Ilsan hospital, Ilsan, , Korea, Republic of

Gachon University Gil Mdical Center, Incheon, , Korea, Republic of

Local Institution - S09, Incheon, , Korea, Republic of

Local Institution - S10, Jeonju-si, , Korea, Republic of

Jeonbuk National University Hospital, JeonJu, , Korea, Republic of

Local Institution - S05, Seoul, , Korea, Republic of

Local Institution - S06, Seoul, , Korea, Republic of

Seoul National University Hospital, Seoul, , Korea, Republic of

Local Institution - S08, Seoul, , Korea, Republic of

Yonsei University Severance Hospital, Seoul, , Korea, Republic of

Asan Medical Center, Seoul, , Korea, Republic of

Local Institution - S12, Seoul, , Korea, Republic of

Samsung Medical Center, Seoul, , Korea, Republic of

Local Institution - S01, Seoul, , Korea, Republic of

The Catholic University, St. Mary's Hospital, Seoul, , Korea, Republic of

Local Institution - S14, Wonju, , Korea, Republic of

Wonju Severance Christian Hospital, Wonju, , Korea, Republic of

Contact Details

Name: Claire (Myoung-Jin) Lee, Medical doctor

Affiliation: Celgene Korea

Role: STUDY_DIRECTOR

Useful links and downloads for this trial

Clinicaltrials.gov

Google Search Results

Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: